Business
Red Light Holland Publishes Report on Psilocybin Microdosing In Collaboration With NUBU Pharmaceuticals Aimed At NUBU's Pharmaceutical's Network Of Medical Doctors In Australasia
Toronto, Ontario--(Newsfile Corp. - April 26, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4...
About this update from Red Light Holland Corp
[{"type":"text","content":"Red Light Holland Publishes Report on Psilocybin Microdosing In Collaboration With NUBU Pharmaceuticals Aimed At NUBU's Pharmaceutical's Network Of Medical Doctors In AustralasiaToronto, Ontario--(Newsfile Corp. - April 26, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (\"Red Light Holland\" or the \"Company\"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce that the Company has, in collaboration with NUBU Pharmaceutical (\"NUBU Pharmaceuticals\"), a leading medical cannabis and medical psychedelic company based in New Zealand, with strong distribution ties to Australia, published a report aimed at educating law makers and a network of medical doctors in Australasia, about the potential benefits of microdosing psilocybin, based on the latest scientific research.\"There's lots of progress in Australia which is why we are pleased to further our partnership with NUBU Pharmaceuticals to produce this report, which we hope will serve as a valuable resource for medical providers in that region. We are committed to following the latest science and using our resources to help raise awareness of the potentially therapeutic effects of microdosing, in both Australia, New Zealand and to any emerging market around the world. Our finger is always on the pulse as we search for potential new opportunities abroad,\" said Todd Shapiro, CEO and Director of Red Light Holland.The report will be presented to NUBU's networks of medical doctors in both Australia and New Zealand, providing a summary of the latest scientific research, best practices, and guidelines to help inform doctors who are interested in helping their patients explore microdosing natural psilocybin for potentially therapeutic benefits. The published report also draws on consensual data collection via Red Light Holland's iMicro app and microdosing events in the Netherlands, as well as the knowledge and experience of the Company's therapist and microdosing expert, Jeff Hamburg.The collaboration between Red Light Holland and NUBU Pharmaceuticals is a significant step towards increasing understandi...